Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A quantum resistant chaos driven image encryption framework for secure visual data transmission in intelligent transportation systems.

Scientific reports·2026
Same author

Development and validation of a digital pathology artificial intelligence (DPAI)-derived risk score predicting Gleason grade group reclassification for patients who are candidates for active surveillance.

Future oncology (London, England)·2026
Same author

Impaired spatial coding and neuronal hyperactivity in the medial entorhinal cortex of aged APP knock-in mice.

Cell reports·2026
Same author

miRNA profiling shows shared signatures in pediatric asthma, obesity and their comorbidity.

Frontiers in immunology·2026
Same author

A Multi-Omics Approach Uncovers Divergent Mechanisms of Asthma in Normal Weight and Obese Children.

Metabolites·2026
Same author

Sustainable EV adoption with clustering and predictive modelling for optimal charging infrastructure in the West Midlands and North East UK.

Scientific reports·2026
Same journal

Court finds no Vaccines-autism link.

Human vaccines·2022
Same journal

Introduction of a second dose of measles in national immunization program in India: a major step towards eradication.

Human vaccines·2012
Same journal

Vaccination against trypanosomiasis: can it be done or is the trypanosome truly the ultimate immune destroyer and escape artist?

Human vaccines·2011
Same journal

Immune response to influenza vaccination in children treated with methotrexate or/and tumor necrosis factor-alpha inhibitors.

Human vaccines·2011
Same journal

Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.

Human vaccines·2011
Same journal

Fighting against infectious diseases in China.

Human vaccines·2011
See all related articles

Related Experiment Video

Updated: May 29, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Recent developments for Pseudomonas vaccines.

Anurag Sharma1, Anja Krause, Stefan Worgall

  • 1Department of Genetic Medicine, Weill Medical College of Cornell University, New York, NY, USA.

Human Vaccines
|September 24, 2011
PubMed
Summary
This summary is machine-generated.

Developing a Pseudomonas aeruginosa vaccine is crucial for immune-compromised patients and cystic fibrosis individuals. Current research reviews vaccine candidates, focusing on mucosal immunity for respiratory tract infections.

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants
11:35

Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants

Published on: May 4, 2018

Related Experiment Videos

Last Updated: May 29, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants
11:35

Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants

Published on: May 4, 2018

Area of Science:

  • Medical Microbiology and Immunology
  • Vaccine Development
  • Infectious Diseases

Background:

  • Pseudomonas aeruginosa infections pose significant health risks, particularly for immunocompromised individuals and those with cystic fibrosis.
  • Despite extensive research, an effective vaccine against P. aeruginosa remains unavailable.
  • Host and pathogen complexities have hindered vaccine development efforts.

Purpose of the Study:

  • To review the current status of vaccine development for Pseudomonas aeruginosa.
  • To focus on strategies for achieving mucosal immunity against respiratory tract infections.
  • To address the challenges in developing a P. aeruginosa vaccine for susceptible populations.

Main Methods:

  • Review of existing literature on P. aeruginosa vaccine candidates.
  • Analysis of preclinical (animal models) and clinical (human) trial data.
  • Evaluation of different vaccine approaches, including sub-cellular fractions, capsule components, and recombinant proteins.

Main Results:

  • Various vaccine candidates targeting P. aeruginosa have been evaluated.
  • Challenges related to host-pathogen interactions and immune responses have been identified.
  • No licensed vaccine is currently available, highlighting the need for further research.

Conclusions:

  • Vaccine development for P. aeruginosa is complex due to unique host and pathogen characteristics.
  • Future strategies should prioritize achieving effective mucosal immunity, especially for cystic fibrosis patients.
  • Continued investigation into novel vaccine platforms and targets is essential.